Impact of rheumatoid arthritis in the public health system in Santa Catarina, Brazil: a descriptive and temporal trend analysis from 1996 to 2009

Gomes, Rafael Kmiliauskis Santos; Pires, Fabio Antero; Nobre, Moacyr Roberto Cucê; Marchi, Mauricio Felippi de Sá; Rickli, Jennifer Cristina Kozechen

doi:10.1016/j.rbre.2016.07.003

Cited by 5 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first restriction refers to the number of RA patients treated by the SUS with biologic medicines. These studies [48,50,56] record data from 1996 facilitated by the MoHB (only 10% of RA patients used biological medicines). The second concerns access in the medicines availability dimension: the restriction rate adopted was 50%, based on published studies and other sources between 1998 and 2005 [57][58][59][60].…”

Section: Values Determined With the Modeled Calculation Of The Budget...mentioning

confidence: 99%

Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

Faleiros

Álvares-Teodoro

Silva

et al. 2021

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Objectives: Budget Impact Analyses (BIA) of medicines helps managers in promoting health systems' sustainability when assessing the role and value of new medicines. However, it is not clear whether BIAs typically underestimate or overestimate the impact on real-world budgets. This retroactive analysis seeks to compare estimated values obtained by a BIA and Real-World Evidence (RWE) to guide discussions. Methods: The estimated values were obtained through a BIA concerning the incorporation of adalimumab for the treatment of Rheumatoid Arthritis into the Brazilian Unified Health System (SUS) carried out retroactively and per international guidelines. RWE data was extracted from SUS computerized systems. We subsequently compared the number of treatments, costs, and Incremental Budget Impact (IBI). Results -The total number of treatments was underestimated by 10% (6,243) and the total expenditure was overestimated by 463% (US$ 4.7 billion). In five years, the total difference between the estimated values and real IBI reached US$ 1.1 billion. A current expenditure of US$ 1.0 was observed for every US$ 5.60 of estimated expenditure. Conclusion -The higher estimates from the BIA might cause decision makers to be more cautious in the introduction of the new drug to reduce the opportunity costs for other interventions.

show abstract

Section: Values Determined With the Modeled Calculation Of The Budget...mentioning

confidence: 99%

Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

Faleiros

Álvares-Teodoro

Silva

et al. 2021

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

“…Brazilian Journal of Development, Curitiba, v.7, n.9, p. 91805-91819 sep. 2021 Dentre estas doenças a artrite reumatoide tem merecido mais atenção pelas consequências que podem causar ao paciente senão tratada corretamente (GOMES, 2017).…”

Section: Introductionunclassified

Revisão sistemática sobre os efeitos fitoterápicos da uncaria tomentosa e uncaria guianensis na artrite reumatoide e osteoartrite / Systematic review on the herbal effects of uncaria tomentosa and uncaria guianensis in rheumatoid arthritis and osteoarthritis

Zeferino¹,

Laurentino²,

Barros³

et al. 2021

BJDV

View full text Add to dashboard Cite

Introdução: A artrite reumatoide (AR) é uma doença crônica, progressiva, autoimune e de causa desconhecida. É caracterizada por inflamação persistente que afeta principalmente as articulações periféricas. Por ser uma doença sem cura, muitos medicamentos, incluindo os fitoterápicos são utilizados na intenção de se ter um controle da doença. Nesse contexto, a Uncaria tomentosa e a Uncaria guianensis são opções utilizadas como tratamento alternativo por populares, uma vez que o fitoterápico atua em processos inflamatórios articulares, pela suas propriedades antioxidantes, antivirais, antiinflamatórias e antirreumáticas.

show abstract

“…In iximab, administered intravenously, was the rst available TNFα inhibitor, and its bene ts in IMID management are well established. National studies performed using administrative databases that document direct expenses for outpatient and drug treatment of autoimmune diseases indicated that medications accounted for 68.72% of the total medical expenditure in patients with rheumatoid arthritis, with the most prescribed biologic medication being in iximab [3]. In Brazil, free access to in iximab is regulated through the Specialized Component of Pharmaceutical Assistance, a strategy to allow access to medicines within the scope of the Uni ed Health System that seeks to guarantee the completeness of treatments at the outpatient level through lines of care de ned in the Clinical Protocols and Therapeutic Guidelines published by the Ministry of Health [4].…”

mentioning

confidence: 99%

Adherence to infliximab treatment in patients with immune-mediated inflammatory diseases from a Referral Center in Brazil: A cohort study

Lauton,

Pereira,

Oliveira

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Infliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However, treatment adherence is essential to achieve the therapeutic objective. This study aimed to determine the rate of adherence to infliximab treatment in patients treated at a referral center at a university hospital. Method This ambispective cohort study included patients treated at the Professor Edgard Santos University Hospital (HUPES) referral center of our university hospital between March 2022 and February 2023. Sociodemographic, clinical, and pharmacotherapeutic data were collected from patients through interviews and medical record reviews using a structured form. The adherence rate was defined as the proportion of days covered in a year. Patients who achieved an adherence rate > 80% were considered adherent. Results The treatment adherence rate was 91.04%. Individuals with inflammatory bowel diseases had a 39.1% higher risk of non-adherence to treatment compared with other patients. Most patients achieved remission or control of the underlying disease activity and had good functional capacities. The main reason for absence on the scheduled date was difficulty traveling to the referral center. Conclusions Despite the reported difficulties, treatment adherence was observed to be high. As the study was conducted in a reference unit with multidisciplinary care and continuous monitoring for treatment effectiveness, safety, and adherence, welcoming and good communication between professionals and patients may have contributed to the high adherence rate.

show abstract

Impact of rheumatoid arthritis in the public health system in Santa Catarina, Brazil: a descriptive and temporal trend analysis from 1996 to 2009

Abstract: During the observed period, a reduction in the number of hospital admissions for both clinical and orthopedic surgical procedures related to this disease was observed. Nevertheless, there was an increase in the cost of medical admissions.

Cited by 5 publications

References 18 publications

Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

Revisão sistemática sobre os efeitos fitoterápicos da uncaria tomentosa e uncaria guianensis na artrite reumatoide e osteoartrite / Systematic review on the herbal effects of uncaria tomentosa and uncaria guianensis in rheumatoid arthritis and osteoarthritis

Adherence to infliximab treatment in patients with immune-mediated inflammatory diseases from a Referral Center in Brazil: A cohort study

Contact Info

Product

Resources

About